Sugi Predict

Sugi Predict / Compounds / SCHEMBL515913

SCHEMBL515913

SCHEMBL515913

C[C@H](N)C(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.57
▸ BCL9 O00512 1/20 0.54
▸ CTNNB1 P35222 1/20 0.54
▸ HTR2A P28223 1/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ PKM P14618 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ CA1 P00915 2/20 0.49
▸ CA2 P00918 2/20 0.49
▸ MGLL Q99685 2/20 0.48
▸ MAPT P10636 2/20 0.47
▸ HGFAC Q04756 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ LMNA P02545 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9435291 1.00 GAA (0.57) GAABCL9CTNNB1HTR2AKMT2A
Water SCHEMBL4754930 0.98 GAA (0.55) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL4805620 0.87 GAA (0.54) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL7613846 0.87 GAA (0.54) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL4683792 0.86 GAA (0.60) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL4752026 0.85 GAA (0.58) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL14307582 0.85 GAA (0.58) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL11478677 0.84 GAA (0.54) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL28440280 0.84 GAA (0.54) GAABCL9CTNNB1HTR2AKMT2A
SCHEMBL23493150 0.84 ELANE (0.55) KMT2APKMALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109554437-A A kind of dual wavelength microbial biochemical reaction dynamic interpretation detection method 湖南长沙天地人生物科技有限公司 2019-04-02 — — CN claimed
CN-109328067-A The CD47 agonist of inducement of apoptosis and its purposes for the treatment of procedure cell death defect related disease 索邦大学 2019-02-12 — — CN claimed
CN-108779150-A The Preparation Method And Their Intermediate of Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2 费森尤斯卡比依普莎姆责任有限公司 2018-11-09 — — CN claimed
CN-106866786-A L p-nitrophenyl alanimamides dipeptidase derivants and its preparation method and application 西南大学 2017-06-20 — — CN claimed
CN-103149351-A Synthesis and application of envelope antigen universal for pyrethriods pesticide UNIV JIANGNAN 2013-06-12 — — CN claimed
CN-102725639-A Positively charged species as binding reagents in the separation of protein aggregates from monomers NOVARTIS AG 2012-10-10 — — CN claimed
US-20110178151-A1 COMPOUNDS AND METHODS OF TREATING OBESITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) 2011-07-21 — — US claimed
EP-2262763-A2 COMPOUNDS AND METHODS OF TREATING OBESITY Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2010-12-22 — — EP claimed
US-20100297680-A1 METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE UNIVERSITY OF WASHINGTON (US) 2010-11-25 — — US claimed
WO-2009109973-A2 COMPOUNDS AND METHODS OF TREATING OBESITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2009-09-11 — — WO claimed
US-20080261250-A1 Methods for Assessing the Risk for Development of Cardiovascular Disease UNIVERSITY OF WASHINGTON (US) 2008-10-23 — — US claimed
EP-1787116-A4 METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE UNIV WASHINGTON (US) 2008-05-28 — — EP claimed
EP-1787116-A1 METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE University of Washington (US) 2007-05-23 — — EP claimed
WO-2006014628-A1 METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE UNIVERSITY OF WASHINGTON (US) 2006-02-09 — — WO claimed
CN-1674899-A Use of IkappaB-kinase inhibitors in pain therapy AVENTIS PHARMA GMBH (DE) 2005-09-28 — — CN claimed
EP-0961779-A1 SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (CA) 1999-12-08 — — EP claimed
WO-1998032766-A1 SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (US) 1998-07-30 — — WO claimed
EP-4743578-A2 THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY Precigen, Inc. (US) 2026-05-20 — — EP disclosed
EP-0157327-A2 Novel compounds for detecting the presence of hydrolytic analytes in a test sample MILES INC. (US) 1985-10-09 — — EP disclosed
US-4499185-A ANALYSIS FOR LEUKOCYTES USING A CHROMOGENIC ESTER AND 3-QUINUCLIDINOL MILES LABORATORIES, INC. (US) 1985-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178151-A1 COMPOUNDS AND METHODS OF TREATING OBESITY GPR119, FABP4, LIPC GAA 281/4885BCL9 3783/4885CTNNB1 3303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.